PALI Stock Price, Chart, Stats & News
Palisade Bio, Inc. (PALI) does not currently pay a dividend.
PALI chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -12.49% |
ROE | -47.76% |
D/E | 0.00x |
Interest coverage ratio | -1805.60x |
PALI valuation
P/E | – |
P/S | – |
P/B | 0.86x |
P/CF | -10.26x |
P/FCF | -30.59x |
P/OCF | -10.26x |
PEG | -0.26x |
EV multiple | -25.76x |
About
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
Similar securities
Based on sector and market capitalization
